CSL Limited (CSLLY)
OTCMKTS · Delayed Price · Currency is USD
68.94
-1.05 (-1.50%)
Aug 28, 2025, 3:45 PM EDT
CSL Limited Revenue
In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B with 5.12% growth. CSL Limited had revenue of $7.08B in the half year ending June 30, 2025, with 15.49% growth.
Revenue
15.56B
Revenue Growth
+5.12%
P/S Ratio
4.32
Revenue / Employee
520.26K
Employees
29,904
Market Cap
67.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Longduoduo Company | 4.99M |
CSL Limited News
- 9 days ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 9 days ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 9 days ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 10 days ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 2 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 3 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 4 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire